biotech

InxMed (Shanghai) Co., Ltd.

Account opportunity

Not established

Relationship

Active signals

Trials as sponsor

Why this account matters

InxMed (Shanghai) Co., Ltd.

New trial — A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

New trialNCT07174908

59/100

Opportunity

Commercial fit12/25

Clinical timing18/20

Biomarker need10/20

Relationship2/10

Signal strength9/10

Account value7/10

Urgency1/5

New phase 3 trial NCT07174908 posted by InxMed (Shanghai) Co., Ltd.: "A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation". New trial on a phase 3 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 189 days ago.

ConfidenceHigh · 95%clinical development · translational medicine · clinical operations

Draft outreach Review

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.

InxMed (Shanghai) Co., Ltd.

New trial — IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

New trialNCT07441174

53/100

Opportunity

Commercial fit11/25

Clinical timing20/20

Biomarker need5/20

Relationship2/10

Signal strength9/10

Account value5/10

Urgency1/5

New phase 1_2 trial NCT07441174 posted by InxMed (Shanghai) Co., Ltd.: "IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors". New trial on a phase 1_2 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 193 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations

Draft outreach Review

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

Trial	Phase	Testing language
NCT07174908 A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation	phase 3	mol. elig.
NCT07441174 IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors	phase 1 2	mol. elig.